Company
Headquarters: Sao Paulo, SP, Brazil
Employees: 16,000
CEO: Ms. Jeane Tsutsui
R$6.34 Billion
BRL as of Jan. 1, 2025
US$1.03 Billion
Company | Market Cap (USD) |
---|---|
Intuitive | $216.79 B |
EssilorLuxottica SA | $116.96 B |
Becton, Dickinson and Company | $69.74 B |
HOYA Corp | $45.26 B |
Alcon Inc. | $41.55 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, and clinical analysis, health management, and medical care areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It offers laboratory and image exam, diagnostic information, check-up and reference laboratory, dental imaging exam, dental radiology, and diagnostic imaging services. As of December 31, 2019, the company had 245 patient service centers and 24 operations in hospitals under the Fleury, Labs a+, Felippe Mattoso, Lafe, a+SP, Campana, Weinman, a+, Serdil, a+ and Diagmax, IRN/ CPC, Diagnosson a+, and Inlab brand names. Fleury S.A. was founded in 1926 and is headquartered in São Paulo, Brazil.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | R$7.46 B |
EBITDA | R$2.11 B |
Gross Profit TTM | R$2.06 B |
Profit Margin | 8.01% |
Operating Margin | 16.96% |
Quarterly Revenue Growth | 19.20% |
Fleury SA has the following listings and related stock indices.
Stock: Bovespa: FLRY3 wb_incandescent